Clair Labs Funding (2026)

Clair Labs was pre-revenue at the time of the November 2021 interview. Berenson confirmed current revenue was zero, as the company was still conducting clinical trials and had not yet received full FDA clearance for commercial deployment.

Clair Labs had no paying customers as of November 2021. The company's target customers are healthcare providers, specifically those managing chronic patients enrolled in Medicare-reimbursed remote patient monitoring programs. Patients themselves do not pay for the device or service.

The addressable patient population for the company's initial COPD indication is 16 million diagnosed patients in the United States. Berenson noted that on average each COPD patient experiences at least one hospitalization per year. As of the interview, 50 prototype devices had been deployed across US clinical trial facilities. Pricing to providers was not disclosed. The company does not offer a consumer product or a free tier.

Clair Labs operates a recurring reimbursement-based revenue model. Rather than selling devices directly to patients or charging providers upfront for hardware, the company receives a share of the reimbursement that Medicare and major private payers provide to healthcare providers enrolled in remote patient monitoring programs.

Berenson stated that a chronic patient recognized under an RPM program generates approximately $150 per month, or $1,800 per year, for the care provider. That reimbursement is composed of several components: device installation, clinician review time, and the monthly fee for digitally collecting patient signals. Berenson said Clair Labs intends to capture a large portion of that $1,800 annual figure per patient. He declined to specify the exact revenue share or the price charged to providers.

The company's initial clinical focus is COPD, a chronic respiratory condition affecting 16 million diagnosed patients in the United States. Berenson cited data from ongoing trials showing that the device raises an accurate alarm flag seven to eight days before a hospitalization event in approximately 95 percent of cases observed in the trial sample. The average cost of a COPD hospitalization is $12,000, and Berenson argued that early intervention with antibiotics or steroids can prevent the hospitalization entirely, making the RPM program economically beneficial to payers. Burn rate and gross margin were not disclosed.

Clair Labs had 13 full-time employees as of November 2021. Berenson described the team as split roughly evenly between researchers and engineers, with himself handling all remaining functions. He characterized the team as lean by design given the capital-intensive nature of hardware and FDA-regulated clinical development.